Alessandro Brancatella
Overview
Explore the profile of Alessandro Brancatella including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
487
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sciarroni E, Montanelli L, Di Cosmo C, Bagattini B, Comi S, Pignata L, et al.
Ital J Pediatr
. 2024 May;
50(1):106.
PMID: 38812002
Background: In this study, we used targeted next-generation sequencing (NGS) to investigate the genetic basis of congenital hypothyroidism (CH) in a 19-year-old Tunisian man who presented with severe hypothyroidism and...
2.
Significance of Thyroglobulin Autoantibodies in Patients With Thyroid Cancer Treated With Lenvatinib
Sgro D, Rossi P, Piaggi P, Brancatella A, Lorusso L, Bottici V, et al.
J Endocr Soc
. 2023 Jul;
7(8):bvad084.
PMID: 37440964
Context: Serum thyroglobulin (Tg) is a highly sensitive and specific tumor marker, employed in post-operative management of patients with differentiated thyroid carcinomas. Tumor shrinkage of radioiodine-refractory thyroid cancer (RAIR-DTC) treated...
3.
Sgro D, Brancatella A, Greco G, Torregrossa L, Piaggi P, Viola N, et al.
J Clin Endocrinol Metab
. 2023 Jun;
108(11):e1186-e1192.
PMID: 37265229
Context: Prognosis is excellent for papillary thyroid carcinoma (PTC), noninvasive follicular thyroid neoplasia with papillary-like nuclear features (NIFT-P), and follicular thyroid carcinoma (FTC) but is poor for poorly differentiated thyroid...
4.
Viola N, Agate L, Caprio S, Lorusso L, Brancatella A, Ricci D, et al.
Endocr Relat Cancer
. 2023 Apr;
30(7).
PMID: 37043372
The relevance of thyroid autoimmunity to the prognosis of papillary thyroid carcinoma is still unsettled. We decided to investigate the impact of thyroid autoimmunity on the prognosis of papillary thyroid...
5.
Brancatella A, Viola N, Santini F, Latrofa F
Best Pract Res Clin Endocrinol Metab
. 2023 Feb;
37(2):101742.
PMID: 36813660
Breakdown of self-tolerance to thyroid antigens (thyroperoxidase, thyroglobulin and the thyrotropin-receptor) is the driver of thyroid autoimmunity. It has been suggested that infectious disease might trigger autoimmune thyroid disease (AITD)....
6.
Brancatella A, Pierotti L, Viola N, Lupi I, Montanelli L, Cremolini C, et al.
Eur Thyroid J
. 2022 May;
11(4).
PMID: 35622442
Objective: Destructive thyroiditis is the most common endocrine immune-related adverse event (iRAEs) in patients treated with anti-PD1/PD-L1 agents. Given its self-limited course, current guidelines recommend no treatment for this iRAE....
7.
Brancatella A, Cappellani D, Kaufmann M, Semeraro A, Borsari S, Sardella C, et al.
J Clin Endocrinol Metab
. 2022 May;
107(8):e3159-e3166.
PMID: 35569070
Background: Pharmacological therapy may be useful in the treatment of moderate to severe hypercalcemia in patients with infantile hypercalcemia-1 (HCINF1) due to pathogenic variants in the cytochrome P450 24 subfamily...
8.
Cappellani D, Brancatella A, Morganti R, Borsari S, Baldinotti F, Caligo M, et al.
Eur J Endocrinol
. 2021 Nov;
186(2):137-149.
PMID: 34735369
Background And Objectives: CYP24A1 encodes a 24-hydroxylase involved in vitamin D catabolism, whose loss-of-function results in vitamin D-dependent hypercalcemia. Since the identification of CYP24A1 variants as a cause of idiopathic...
9.
Brancatella A, Viola N, Rutigliano G, Sgro D, Santini F, Latrofa F
J Endocr Soc
. 2021 Aug;
5(10):bvab130.
PMID: 34458656
Context: Acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been related to subacute thyroiditis (SAT). Objective: We compared SAT cases during the SARS-CoV-2 pandemic to those observed in the previous years....
10.
Brancatella A, Lupi I, Montanelli L, Ricci D, Viola N, Sgro D, et al.
J Endocr Soc
. 2021 Aug;
5(9):bvab093.
PMID: 34337277
Context: Thyrotoxicosis is a common immune-related adverse event in patients treated with programmed cell death protein-1 (PD1) or programmed cell death protein ligand-1 (PD-L1) blockade. A detailed endocrinological assessment, including...